We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Rockefeller Foundation Lays Out Massive COVID-19 Testing Action Plan for US

By LabMedica International staff writers
Posted on 22 Apr 2020
Print article
Illustration
Illustration
The Rockefeller Foundation (New York, NY, USA) has laid out a National COVID-19 Testing Action Plan which outlines the precise steps necessary to enact robust testing, tracing, and coordination to more safely reopen the US economy – starting with a dramatic expansion of testing from one million tests per week to initially three million per week and then 30 million per week. The effort will be backed by an Emergency Network for COVID-19 Testing to coordinate and underwrite the testing market, a public-private testing technology accelerator, and a national initiative to rapidly expand and optimize the use of US, university, and local lab capacity. The goal of the Action Plan is to build a state-led national program of COVID-19 testing that supports reopening the US economy through the goals of work-force monitoring, early detection of recurrent outbreaks, and diagnostic and home testing. This would be the largest public health testing pro-gram in American history and its success will depend on the active engagement of the government, business, philanthropy, and the public.

In the past two weeks, the Rockefeller Foundation has brought together experts and leaders from science, industry, academia, public policy, and government – across sectors and political ideologies – to create a clear, pragmatic, data-driven, actionable plan to beat back COVID-19 and get Americans back to work more safely. The Rockefeller Foundation believes that testing is the way out of this crisis, and instead of ricocheting between an unsustainable shutdown and a dangerous, uncertain return to normalcy, the US must mount a sustainable strategy with better tests and contact tracing, and stay the course for as long as it takes to develop a vaccine or cure.

The Rockefeller Foundation and its finance partners will help create an emergency procurement network, the Emergency Network for Covid-19 Testing, that can leverage public-private credit guarantees, define pooled procurement requirements for critical testing and supplies and negotiate medium term (3-6 month) contracts with suppliers to make sure large volumes of critical supplies are accessible to purchasing cooperatives, health systems, state and local governments, working alone or together, and other buyers. The aim of the ENCT would be to support and complement the work of federal and state agencies by engaging with producers of testing equipment, reagents, and other lab consumables; national, state and local purchasers; public and private healthcare funders; and financial institutions. The intent is to overcome market, government, logistical, and diagnostic industry challenges that have plagued the dramatic scale up in COVID-19 diagnostic testing required to reopen the US economy.

The Action Plan also includes launching a Covid Community Healthcare Corps so that every American can easily get tested with privacy-centric contact tracing; a testing data commons and digital platform to track COVID-19 statuses, resources, and effective treatment protocols across states and be a clearinghouse for data on new technologies; and a Pandemic Testing Board, in line with other recommendations, to bridge divides across governmental jurisdictions and professional fields.

Related Links:
The Rockefeller Foundation

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: A one-step confirmatory laboratory test could definitively diagnose active syphilis infection within 10 minutes (Photo courtesy of Adobe Stock)

First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes

In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.